[Federal Register Volume 62, Number 93 (Wednesday, May 14, 1997)]
[Notices]
[Pages 26516-26520]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 97-12607]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention
[Program Announcement Number 801]


Cooperative Agreements to Conduct Research and Education Programs 
on Lyme Disease in the United States

Introduction

    The Centers for Disease Control and Prevention (CDC) announces the 
expected availability of FY 1998 funds for a cooperative agreement 
program to conduct research on Lyme disease and illnesses caused by 
other related Borrelia species. Topics include: disease surveillance 
and epidemiologic studies, ecologic studies, and the development, 
implementation, and evaluation of prevention/control strategies. In 
addition, funds are available for the development of educational 
programs. This program's overall objective is to lower the incidence of 
Lyme disease in hyperendemic states to 5 per 100,000 population or less 
by the year 2000.
    CDC is committed to achieving the health promotion and disease 
prevention objectives of ``Healthy People 2000,'' a national activity 
to reduce morbidity and mortality and improve the quality of life. This 
announcement is related to the priority area of Immunization and 
Infectious Diseases. (For ordering a copy of ``Healthy People 2000,'' 
see the Section ``Where to Obtain Additional Information.'')

Authority

    This program is authorized under Sections 301 and 317(k)(2) of the 
Public Health Service Act, as amended (42 U.S.C. 241 and 247b(k)(2)).

Smoke-Free Workplace

    CDC encourages all grant recipients to provide a smoke-free 
workplace and to promote the non-use of all tobacco products. Public 
Law 103-227, the Pro-Children Act of 1994, prohibits smoking in certain 
facilities that receive Federal funds in which education, library, 
daycare, health care, and early childhood development services are 
provided to children.

Eligible Applicants

    Applications may be submitted by public and private nonprofit 
organizations and governments and their agencies within the United 
States. Thus, universities, colleges, research institutions, hospitals, 
other public and private organizations, State and local health 
departments, or their bona fide agents, federally recognized Indian 
tribal governments, Indian tribes or Indian tribal organizations, and 
small, minority and/or women-owned, nonprofit businesses are eligible 
to apply as the principal investigating entities. These United States 
entities may propose collaborative arrangements with investigators 
outside the United States, provided the proposal has a direct impact on 
United States public health.
    Participation in proposed activities by scientists, health 
professionals and educators with expertise and experience in Lyme 
disease and its associated epidemiologic, environmental and 
entomological aspects is desirable. In addition, combined program 
activities involving State and local health departments, universities, 
colleges, and private nonprofit organizations are encouraged.

    Note: Effective January 1, 1996, Public Law 104-65 states that 
an organization described in section 501(c)(4) of the Internal 
Revenue Code of 1986 which engages in lobbying activities will not 
be eligible for the receipt of Federal funds constituting an award, 
grant, cooperative agreement, contract, loan, or any other form.

Availability of Funds

    CDC projects approximately $1,700,000 of the President's budget 
will be available for FY 1998 for cooperative agreements to conduct 
research and education programs on Lyme disease in the United States. 
However, this announcement is made prior to the actual appropriation of 
fiscal year 1998 funds to allow new and competing continuation 
applicants sufficient time to prepare applications, and to enable 
timely award of the cooperative agreements. Approximately 10 to 15 new 
and competing continuation awards will be made with a median award of 
$150,000 ranging from $50,000 to $250,000. It is expected that the 
awards will begin on or about February 15, 1998. Awards will be funded 
for a 12-month budget period within a project period of up to three 
years. Funding estimates may vary and are subject to change. 
Continuation awards within the project period are made on the basis of 
satisfactory progress and the availability of funds.
    Applicants may apply for and receive support for activities under 
one or more of the three activity areas (A.1., A.2., and/or A.3.) 
listed in the Recipient Activities section. Approximately 35% of the 
available funds will be allocated to develop improved disease 
surveillance and conduct epidemiologic studies; approximately 40% of 
the available funds will be allocated to conduct ecologic studies and 
develop and implement strategies for prevention and control; and, 
approximately 25% of the available funds will be allocated to educate 
the public and health professionals on the primary and secondary 
prevention of Lyme disease. Applications may be submitted for any or 
all of the activities described above (any one or combination of the 
three subjects areas). Each category will be scored separately.

Recipient Financial Participation

    There are no matching or cost participation requirements; however, 
the applicant's anticipated contribution to the overall program costs, 
if any, should be provided on the application. These funds should not 
supplant existing expenditures in this disease area.

Background

    Lyme disease is one of the most important emerging infectious 
diseases in the United States, accounting for more than 90% of all 
reported vector-borne illness. The numbers of reported cases have 
increased steadily, resulting in a thirty-fold rise between 1982 and 
1996. More than 16,000 cases were reported by 44 States to the CDC in 
1996.
    Lyme borreliosis is a potentially serious and debilitating 
infection that may lead to subacute and chronic disease of the joints, 
the peripheral and central nervous system, the heart, and the skin. 
Questions have been raised about microbial persistence and chronic Lyme 
disease. Although transplacental transmission has been reported, 
epidemiologic studies have not shown an association between Lyme 
disease and adverse outcomes of pregnancy.
    Lyme disease cases have been reported nationwide; however, the 
disease is concentrated in three regions: the northeast and mid-
Atlantic, the north central, and the Pacific coastal regions. 
Distribution of cases is principally related to the density of infected 
tick vectors. Ixodes scapularis is the principal vector throughout the 
northeastern, mid-Atlantic, and north central States, and is the cause 
of

[[Page 26517]]

significant peridomestic transmission. Ixodes pacificus transmits the 
disease in Pacific coastal areas. Ixodes spinipalpis maintains an 
enzootic cycle in Colorado and California. The role of the putative 
vectors in southern regions of the United States, Ixodes scapularis and 
Amblyomma americanum, is not clear.
    CDC has maintained a system of national surveillance for Lyme 
disease since 1982. This system depends upon reporting of cases by 
State health departments to CDC. It provides basic descriptive 
epidemiologic information, defines trends in established endemic areas, 
and monitors the emergence of the disease in new areas. The usefulness 
of these surveillance data is limited by the application among States 
of different surveillance methods--some active, some passive. In 
addition, there is considerable lack of detection, under-reporting, and 
misclassification of cases. The national surveillance system has not 
provided reliable estimates of the total disease burden, but has given 
a rough index for monitoring trends of incidences. The emergence of the 
disease in new areas has been linked with geographic spread and 
increased density of infected tick vectors, although the dynamics of 
emergence are poorly understood.
    There exists a great need to improve surveillance of human cases, 
to identify and characterize the cycle of transmission among animal 
reservoirs and arthropod vectors, to better define the geographic 
distribution and ecologic determinants of these cycles throughout the 
United States, and to quantify the risk of transmission to persons 
under various circumstances of exposure. Epidemiologic and behavioral 
studies are needed to better define risk factors for human infection so 
that more effective strategies for prevention and control of disease 
can be devised and implemented.
    Research is needed on primary strategies involving community 
participation in integrated pest management (suppression of tick 
vectors, environmental modification, and vertebrate host management), 
personal protection measures to reduce human contact with infected 
ticks, the targeting, cost-benefits, and impact of anticipated 
vaccines, and other specific prevention methods.
    Education of the public and health care professionals is a 
principal goal leading to primary prevention, and to secondary 
prevention through early detection, diagnosis, and appropriate 
treatment of infected persons. The effectiveness of education in 
preventing infection under various circumstances of exposure, such as 
periresidential, recreational, and occupational, needs to be evaluated 
or adequately described in terms of health behavior.

Purpose

    The purposes of these cooperative agreements are to: (1) Provide 
assistance in determining the incidence and trends of Lyme disease in 
various geographic regions of the United States, (2) measure the public 
health impact of early and late stages of Lyme disease, (3) assess risk 
factors associated with the transmission of the disease, including 
behavioral and environmental factors, (4) determine the distribution 
and density of vector tick species, determine B. burgdorferi infection 
rates of these vectors, and characterize the ecologic factors which 
result in high infection rates in tick and vertebrate host populations, 
(5) develop, implement, and evaluate more effective prevention and 
control strategies using a community intervention approach, and (6) 
educate health professionals and the public on prevention through 
personal protection and environmental interventions, and on the need 
for early and accurate diagnosis, and appropriate treatment.

Program Requirements

    In conducting activities to achieve the purpose of this program, 
the recipient will be responsible for conducting selected activities 
under A.1., A.2., and/or A.3. below, and CDC will be responsible for 
conducting activities under B., below:

A. Recipient Activities

1. Disease Surveillance and Epidemiologic Studies (Conduct One or More 
of the Following):
    a. Implement, maintain, and evaluate an active Lyme disease 
surveillance system based on the 1990 (or subsequent) national case 
definition adopted by the Council of State and Territorial 
Epidemiologists (CSTE). Determine the utility of laboratory-based 
surveillance using standardized serologic tests for Lyme disease.
    b. Conduct epidemiologic studies, utilizing descriptive, 
correlative, analytical and seroepidemiologic methods to better 
understand the epidemiology of the disease and to elucidate risk 
factors for infection and disease in specific geographic foci.
    c. Carry out studies to measure the public health burden of Lyme 
disease and to determine the efficacy of various intervention 
strategies for primary and secondary prevention.
    d. Conduct studies to identify human populations at high risk of 
infection and disease, including risks from periresidential, 
occupational, and recreational exposures, and design studies to measure 
the costs and benefits of various intervention strategies, including 
behavior modification, integrated pest management, and vaccine use.
    e. Conduct studies to identify and describe the emergence of Lyme 
disease in previously nonendemic regions.
2. Conduct Ecologic Studies, Develop and Evaluate Prevention/Control 
Strategies (Conduct One or More of the Following):
    a. Initiate ecologic studies that will contribute information for 
development of a nationwide map of Lyme disease risk based on ecologic, 
entomologic, and epidemiologic data. Risk factors to be evaluated may 
include distribution of vector ticks, density of vector ticks, 
infection rate of vector ticks, efficiency of transmission of Lyme 
disease spirochetes, reservoir competence of vertebrate hosts of B. 
burgdorferi, density distribution of principal tick maintenance hosts, 
and contact between infected ticks and humans.
    b. Design, implement, and evaluate an Integrated Pest Management 
(IPM) program that can be used to reduce Lyme disease in residential 
and/or recreational settings. The proposed methods may include 
community participation, acaricides in an area-wide or host-targeted 
applications, alternative acaricides, habitat modification, host 
management, or biological control. Emphasis should be placed on 
adapting the use of an IPM program to communities or large scale 
recreational areas.
    c. Evaluate in tick and animal models whether commercial Lyme 
disease vaccine preparations protect against various strains of B. 
burgdorferi and closely related Borrelia species found in common 
anthropophilic ticks in the United States. Develop anti-tick vaccines 
that interrupt transmission of Ixodes scapularis-borne pathogens.
    d. Culture and characterize the newly described spirochete B. 
lonestari found in Amblyomma americanum ticks. Determine whether this 
spirochete infects and causes disease in vertebrates, including humans.
3. Develop and Disseminate Prevention and Control Information on Lyme 
Disease (Conduct One or More of the Following):
    a. Provide information for health care providers and the public on 
the distribution of Lyme disease in the geographic area being served by 
the applicant. Update these data annually,

[[Page 26518]]

showing trends of incidence and other descriptive epidemiologic 
characteristics of the disease in tabular and map formats.
    b. Devise new and innovative methods for disseminating currently 
developed educational materials to health care providers and the 
general public on measures to prevent Lyme disease and on the early and 
appropriate diagnosis and management of Lyme disease.
    c. Develop informational materials for specific geographical areas 
on the ecology, environmental and behavioral risk factors, and 
prevention of Lyme disease.
     d. Develop and publish information outlining practical methods to 
reduce vector tick densities, based on research in residential areas of 
high Lyme disease transmission.
    e. Devise new and innovative methods to educate physicians, nurses, 
physician assistants, and other front line health care providers about 
Lyme disease, especially those that serve populations at high risk 
because of periresidential, occupational or recreational exposures.
    f. Devise new and innovative health communication methods to 
increase awareness and knowledge of the general public about prevention 
and control of Lyme disease.

B. CDC Activities

    1. Provide technical assistance in the design and conduct of 
research.
    2. Assist in performing selected laboratory tests, as appropriate, 
depending on the needs of the recipient.
    3. Assist in the coordination of research activities among 
different recipient sites.
    4. Assist in the analysis of research data.
    5. Assist in reviewing educational materials for medical and 
scientific accuracy.

Technical Reporting Requirements

    Semiannual progress reports are required and must be submitted no 
later than 30 days after each semiannual reporting period. The 
semiannual progress reports must include the following for each 
program, function, or activity involved: (1) A comparison of actual 
accomplishments to the goal established for the period; (2) the reasons 
for failure, if established goals were not met; and (3) other pertinent 
information including, when appropriate, analysis and explanation of 
performance costs significantly higher than expected. The final 
progress report is required no later than 90 days after the end of the 
project period. All manuscripts published as a result of the work 
supported in part or whole by the cooperative agreement will be 
submitted with the progress reports.
    An annual Financial Status Report (FSR) is required no later than 
90 days after the end of each budget period.
    An original and two copies of all reports should be submitted to 
the Grants Management Branch, CDC.

Application Content

    Applicants may apply for assistance for projects in one or more of 
the subject areas as described in the Recipient Activities section. If 
the applicant is applying under more than one subject area, a separate 
narrative, budget, and budget justification must be submitted for each 
subject area. Each application should consist of the following:
    1. The abstract should summarize the background, needs, goals, 
objective and methods of the proposal on one page.
    2. The program narrative should include the following sections: 
background, objectives, methods, plan of operation, and plan of 
evaluation. List and briefly describe specific, measurable, realistic, 
and time-phased objectives.
    3. A budget justification is required for all budget items and must 
be submitted with Standard Form 424A, ``Budget Information,'' as part 
of PHS 5161-1 (Revised 7/92). The budget should include the total funds 
requested for the project, with separate budgets and justifications for 
each recipient activity/component, i.e., surveillance and 
epidemiological studies; ecologic studies and prevention and control 
activities; and education (development and dissemination of disease 
information). For applicants requesting funding for subcontracts, 
include the name of the person or organization to receive the 
subcontract, the method of selection, the period of performance, and a 
description of the subcontracted service requested.
    4. If the proposed project involves human subjects, whether or not 
exempt from Department of Health and Human Services (DHHS) regulations, 
describe in the narrative adequate procedures for the protection of 
human subjects.
    5. Also, ensure that women, racial and ethnic minority populations 
are appropriately represented in applications for research involving 
human subjects by including a description of the composition of the 
proposed study population (for example, addressing the inclusion of 
women and members of minority groups and their sub-populations in the 
section that will describe the research design). The applicant will 
provide an explanation when the investigator cannot control the race, 
ethnicity and/or sex of the subjects. See Other Requirements for 
additional information.
    When applicable, letters of support must be included in an appendix 
if applicants anticipate the participation of other organizations or 
political subdivisions in conducting proposed activities. Specific 
roles and responsibilities must be delineated.

Notice of Intent To Apply

    In order to assist CDC in planning for and executing the evaluation 
of applications submitted under this Program Announcement, all parties 
intending to submit an application are requested to inform CDC of their 
intention to do so no later than June 13, 1997. Notification should 
include: (1) Name and address of institution, (2) name, address and 
telephone number of contact person, and (3) which recipient 
activity(ies) application will be submitted under. Notification may be 
provided by facsimile or postal mail to Sharron P. Orum, Grants 
Management Officer, Grants Management Branch, Centers for Disease 
Control and Prevention (CDC), 255 East Paces Ferry Road, NE., Room 305, 
Mailstop E-18, Atlanta, GA 30305, facsimile (404) 842-6513.

Required Format for Applications

    Due to the need to reproduce copies of the applications for the 
reviewers, ALL pages of the application MUST be in the following 
format.
    1. The original and two copies must be UNSTAPLED and UNBOUND.
    2. ALL pages must be clearly numbered, and a complete index to the 
application and its appendices must be included.
    3. Begin each separate section on a new page.
    4. All materials must be typewritten, single-spaced, using a font 
no smaller than a size 10, and typed ONLY on 8\1/2\'' by 11'' paper.
    5. Any reprints, brochures, or other enclosures must be copied onto 
8\1/2\'' by 11'' paper by the applicant.
    6. All pages must be printed on ONE side only, with at least 1'' 
margins, headers, and footers.
    7. The application narrative for each recipient activity subject 
area (of the three subject areas) must be limited to 10 pages, 
excluding abstract, budget, and appendices.
    8. Materials that are part of the basic plan must not be placed in 
the appendices.
    9. If the applicant is applying for assistance for more than one of 
the three

[[Page 26519]]

focus areas/components, a separate narrative and budget must be 
submitted for each focus area/component.

Evaluation Criteria

Evaluation Criteria for Proposals for Activity A.1., Disease 
Surveillance and Epidemiological Studies; Activity A.2., Ecologic 
Studies and Prevention/Control Strategies

    Applications will be reviewed and evaluated according to the 
following criteria: (Total 100 points).
    1. The applicant's understanding of the purpose of the proposed 
activity and the feasibility of accomplishing the outcomes desired. (5 
points)
    2. The extent to which background information and other data 
demonstrate that the applicant has the appropriate organizational 
structure, administrative support, and technical expertise to conduct 
the work proposed and has access to stated target populations or other 
study objects. (10 points)
    3. The degree to which the proposed objectives are consistent with 
the purpose as defined in the ``Purpose'' section of this application 
and are specific, measurable, and time-phased. (5 points)
    4. The degree to which the research plans will enable the applicant 
to achieve the stated objectives. The plans should specify the who, 
what, where, how, and timing for the start and completion of each 
activity. (25 points)
    5. The quality of the research methods and instruments to be used. 
(If the proposal involves human subjects, the degree to which the 
applicant has met CDC Policy requirements regarding the inclusion of 
women, ethnic, and racial groups in the proposed research will be 
evaluated. This includes: (1) The proposed plan for the inclusion of 
both sexes and racial and ethnic minority populations for appropriate 
representation; (2) the proposed justification when representation is 
limited or absent; (3) a statement as to whether the design of the 
study is adequate to measure differences when warranted; and (4) a 
statement as to whether the plans for recruitment and outreach for 
study participants include the process of establishing partnerships 
with community(ies) and recognition of mutual benefits.) (25 points)
    6. The quality of the proposed methods for evaluating the project. 
(5 points)
    7. The extent to which qualifications (including expertise and 
experience in relevant work) of project personnel, and the projected 
level of effort by each toward accomplishment of the proposed 
activities demonstrate the ability to successfully conduct the proposed 
work. (10 points)
    8. The degree to which the proposal addresses one or more of the 
priority funding areas:
    a. Surveillance and epidemiological studies that target geographic 
areas of high endemicity/enzooticity and human populations at high 
risk, and populations in circumstances of emerging risk (5 points);
    b. The development, implementation, and evaluation of community-
based strategies of primary prevention and control, including methods 
for vector suppression and personal protection (5 points);
    c. Studies that measure the public health impact of Lyme disease, 
or that estimate the costs and benefits of various strategies of 
prevention and control, including vaccination (5 points).
    9. The extent to which the budget is reasonable, clearly justified, 
and consistent with the intended use of cooperative agreement funds. 
(not scored)

Evaluation Criteria for Proposals for Activity A.3., Development and 
Dissemination of Disease Information/Education

    Applications will be reviewed and evaluated according to the 
following criteria: (Total 100 points)
    1. The applicant's understanding of the purpose of the proposed 
educational intervention/activity and the feasibility of accomplishing 
the outcomes desired. (10 points)
    2. The extent to which background information and other data 
demonstrate that the applicant has the appropriate organizational 
structure, administrative support, and technical expertise to research, 
design, develop, and disseminate the proposed educational materials, 
and to access appropriate target populations. (15 points)
    3. The degree to which the proposed objectives are consistent with 
the defined purpose as defined in the ``Purpose'' section of this 
application and are specific, measurable, and time-phased. (10 points)
    4. The degree to which the educational research, design, 
development, and dissemination plans demonstrate the ability of the 
applicant to achieve the stated objectives. The plan will specify the 
who, what, where, how, and timing for the start and completion of each 
activity. (20 points)
    5. The quality of the educational research, design, development, 
and dissemination methods and instruments to be used. (If the proposal 
involves human subjects, the following will be evaluated: the degree to 
which the applicant has met CDC Policy requirements regarding the 
inclusion of women, ethnic, and racial groups in the proposed research. 
This includes: (1) The proposed plan for the inclusion of both sexes 
and racial and ethnic minority populations for appropriate 
representation; (2) the proposed justification when representation is 
limited or absent; (3) a statement as to whether the design of the 
study is adequate to measure differences when warranted; and (4) a 
statement as to whether the plans for recruitment and outreach for 
study participants include the process of establishing partnerships 
with community(ies) and recognition of mutual benefits. (20 points)
    6. The soundness of the proposed methods for measuring changes in 
behavior and prevention effectiveness of the educational activity/
intervention, including the pre-and post-testing of a representative 
sample of the intended target population. (15 points)
    7. The extent to which qualifications (including training and 
experience in work with Lyme disease) of project personnel, and the 
projected level of effort by each toward accomplishment of the proposed 
activities are described. (10 points)
    8. The extent to which the budget is reasonable, clearly justified, 
and consistent with the intended use of cooperative agreement funds. 
(not scored)

Funding Priorities

    Priority will be given to applications in the areas of surveillance 
and epidemiologic studies that target geographic areas of high 
endemicity/enzooticity and human populations at high risk; to 
applications that relate to studies of community-based strategies of 
primary prevention and control, including methods for vector 
suppression and personal protection; and to applications which focus on 
education of health care providers and on the evaluation of education 
effectiveness.
    Interested persons are invited to comment on the proposed funding 
priorities. All comments received on or before June 26, 1997, will be 
considered before the final funding priorities are established. If any 
funding priority should change as a result of any comments received, a 
revised Announcement will be published in the Federal Register and 
revised applications will be accepted prior to the final receipt of 
applications.
    Written comments should be addressed to: Sharron Orum, Grants 
Management Officer, Grants

[[Page 26520]]

Management Branch, Procurement and Grants Office, Centers for Disease 
Control and Prevention (CDC), 255 East Paces Ferry Road, NE., Room 305, 
Mailstop E-18, Atlanta, GA 30305. All comments should reference the 
Program Announcement Number 801.

Executive Order 12372 Review

    This program is not subject to the Executive Order 12372 review.

Public Health System Reporting Requirements

    This program is not subject to the Public Health System Reporting 
Requirements.

Catalog of Federal Domestic Assistance Number

    The Catalog of Federal Domestic Assistance Number is 93.942.

Other Requirements

Paperwork Reduction Act

    Projects that involve collection of information from 10 or more 
individuals and funded by cooperative agreements will be subject to 
review and approval by the Office of Management and Budget (OMB) under 
the Paperwork Reduction Act.

Human Subjects

    If the proposed project involves research on human subjects, the 
applicant must comply with the Department of Health and Human Services 
Regulations (45 CFR Part 46) regarding the protection of human 
subjects. Assurance must be provided which demonstrates that the 
project will be subject to initial and continuing review by an 
appropriate institutional review committee. In addition to other 
applicable committees, Indian Health Service (IHS) institutional review 
committees also must review the project if any component of IHS will be 
involved or will support the research. If any American Indian community 
is involved, its Tribal government must also approve that portion of 
the project applicable to it. The applicant will be responsible for 
providing evidence of this assurance in accordance with the appropriate 
guidelines and forms provided in the application kit.

Animal Subjects

    If the proposed project involves research on animal subjects, the 
applicant must comply with the ``PHS Policy on Humane Care and Use of 
Laboratory Animals to Awardee Institutions.'' An applicant organization 
proposing to use vertebrate animals in CDC-supported activities must 
file an Animal Welfare Assurance with the Office for the Protection 
from Research Risks at the National Institutes of Health.

Women, Racial and Ethnic Minorities

    It is the policy of the Centers for Disease Control and Prevention 
(CDC) and the Agency for Toxic Substances and Disease Registry (ATSDR) 
to ensure that individuals of both sexes and the various racial and 
ethnic groups will be included in CDC/ATSDR-supported research projects 
involving human subjects, whenever feasible and appropriate. Racial and 
ethnic groups are those defined in OMB Directive No. 15 and include 
American Indian, Alaskan Native, Asian, Pacific Islander, Black and 
Hispanic. Applicants will ensure that women, racial and ethnic minority 
populations are appropriately represented in applications for research 
involving human subjects. Where clear and compelling rationale exist 
that inclusion is inappropriate or not feasible, this situation must be 
explained as part of the application. This policy does not apply to 
research studies when the investigator cannot control the race, 
ethnicity and/or sex of subjects. Further guidance to this policy is 
contained in the Federal Register, Vol. 60, No. 179, pages 47947-47951, 
dated Friday, September 15, 1995.

Application Submission and Deadline

    The original and two copies of the application form PHS 5161-1 
(Revised 7-92, OMB number 0937-0189) must be submitted to Sharron Orum, 
Grants Management Officer, Grants Management Branch, Procurement and 
Grants Office, Centers for Disease Control and Prevention (CDC), 255 
East Paces Ferry Road, NE., Room 305, Mailstop E-18, Atlanta, GA 30305, 
on or before August 1, 1997.
    1. Deadline: Applications will be considered as meeting the 
deadline if they are either:
    a. Received on or before the deadline date; or
    b. Sent on or before the deadline date and received in time for 
submission to the objective review group. (Applicants must request a 
legibly dated U.S. Postal Service postmark or obtain a legibly dated 
receipt from a commercial carrier or the U.S. Postal Service. Private 
metered postmarks will not be acceptable as proof of timely mailing).
    2. Late Applications: Applications which do not meet the criteria 
in 1.a. or 1.b. above are considered late applications. Late 
applications will not be considered and will be returned to the 
applicant.

Where To Obtain Additional Information

    To receive additional written information, call (404) 332-4561. You 
will be asked to leave your name, address, and telephone number. Please 
refer to Announcement #801. You will receive a complete program 
description, information on application procedures and application 
forms. If you have questions after reviewing the contents of all the 
documents, business management technical assistance may be obtained 
from Gladys T. Gissentanna, Grants Management Specialist, Grants 
Management Branch, Procurement and Grants Office, Centers for Disease 
Control and Prevention (CDC), 255 East Paces Ferry Road, NE., Room 314, 
Mailstop E-18, Atlanta, GA 30305, telephone (404) 842-6801. 
Programmatic technical assistance may be obtained from David Dennis, 
M.D. or Duane Gubler, Sc.D., Division of Vector-Borne Infectious 
Diseases, National Center for Infectious Diseases, Centers for Disease 
Control and Prevention (CDC), Fort Collins, CO 80522, telephone (970) 
221-6400. You may also obtain this announcement from one of two 
Internet sites on the actual publication date: CDC's homepage at http:/
/www.cdc.gov or the Government Printing Office homepage (including free 
on-line access to the Federal Register at http://www.access.gpo.gov). 
Other CDC Announcements are also listed on the Internet on the CDC 
homepage.
    Please refer to Announcement Number 801 when requesting information 
and submitting an application.
    Potential applicants may obtain a copy of ``Healthy People 2000'' 
(Full Report, Stock No. 017-001-00474-0) or ``Healthy People 2000'' 
(Summary Report, Stock No. 017-001-00473-1) referenced in the 
``Introduction'' through the Superintendent of Documents, Government 
Printing Office, Washington, D.C. 20402-9325, telephone (202) 512-1800.

    Dated: May 8, 1997.
Joseph R. Carter,
Acting Associate Director for Management and Operations, Centers for 
Disease Control and Prevention (CDC).
[FR Doc. 97-12607 Filed 5-13-97; 8:45 am]
BILLING CODE 4163-18-P